CYduct Diagnostics, Inc. (CYDX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | - | 0 | - |
| Operating profit | $m | -0 | -0 | ||||||
| Net profit | $m | -0 | -0 | -0 | -0 | -0 | - | -0 | - |
| EPS reported | $ | -0.08 | -0.04 | ||||||
| Operating cashflow per share | $ | -0.01 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.01 | 0.00 | ||||||
| Free cash flow | $m | -0 | 0 | ||||||
| Net debt | $m | 1 | 1 | ||||||
| Book value equity | $m | -3 | -1 | ||||||
| Book value per share | $ | -0.54 | -0.08 | ||||||
| Number of shares | m | 5.24 | 12.78 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.97 | -1.25 | ||||||
| P/S LTM | x | 38.58 | 18.78 | ||||||
| P/FCF LTM | x | -37.89 | 114.99 | ||||||
| EV/EBITDA LTM | x | -9.27 | -10.35 | ||||||
| EV/Sales LTM | x | 28.77 | 109.59 | ||||||
| Earnings Yield LTM | % | -31.31% | -5.38% | ||||||
| FCF Yield | % | -2.64% | +0.87% | ||||||
| Quality | |||||||||
| ROE | % | +14.73% | +11.90% | ||||||
| ROIC | % | +17.33% | +12.81% | ||||||
| Operating margin | % | -5.14% | -4.59% | ||||||
| Gross margin | % | +66.19% | +60.66% | ||||||
| FCF/Sales | % | -101.83% | +15.66% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -16.33% | -0.45% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.10 | 0.02 | ||||||
| Net Debt/EBITDA | x | -1.96 | -2.35 | ||||||
| EBIT/Net interest | x | -7.21 | -5.81 | ||||||
| Net debt/market cap | % | +53.99% | +10.91% | ||||||
| Net debt/Equity | x | -0.25 | -0.66 | ||||||
| Gross debt/equity | x | -0.25 | -0.67 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
CYduct Diagnostics, Inc. operates as a medical instrument enterprise that engineers and commercializes a diverse range of technologies, equipment, and methodologies. These innovations are purposed for the detection, diagnosis, therapeutic intervention, and general management of various health conditions and illnesses. The company's extensive product offerings include specialized breast endoscopy systems, an assortment of camera solutions (such as 3-chip and 1-chip models), and all necessary accessories. They also provide a broad selection of endoscopic instruments, encompassing surgical tools like dissectors, graspers, scissors, needle holders, fan retractors, cautery devices, and insufflation needles. Furthermore, CYduct supplies illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps, alongside insufflators. For surgical specialties, their portfolio features laparoscopic instruments designed for general surgery, lymphadenectomy, gynecology, and thorascopy. Complementing these are rigid scopes (like laparoscopes, operative scopes, and cystoscopes) with their corresponding accessories, as well as trocar and cannula sets, video carts, and both insulated and non-insulated instrument handles. Uniquely, the company also provides instrumentation tailored for veterinary applications. Established in 1986, CYduct Diagnostics, Inc. is headquartered in Westport, Connecticut. The firm was formerly known as Solos Endoscopy, Inc., before adopting its current name in December 2020.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CYduct Diagnostics, Inc. operates as a medical instrument enterprise that engineers and commercializes a diverse range of technologies, equipment, and methodologies. These innovations are purposed for the detection, diagnosis, therapeutic intervention, and general management of various health conditions and illnesses. The company's extensive product offerings include specialized breast endoscopy systems, an assortment of camera solutions (such as 3-chip and 1-chip models), and all necessary accessories. They also provide a broad selection of endoscopic instruments, encompassing surgical tools like dissectors, graspers, scissors, needle holders, fan retractors, cautery devices, and insufflation needles. Furthermore, CYduct supplies illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps, alongside insufflators. For surgical specialties, their portfolio features laparoscopic instruments designed for general surgery, lymphadenectomy, gynecology, and thorascopy. Complementing these are rigid scopes (like laparoscopes, operative scopes, and cystoscopes) with their corresponding accessories, as well as trocar and cannula sets, video carts, and both insulated and non-insulated instrument handles. Uniquely, the company also provides instrumentation tailored for veterinary applications. Established in 1986, CYduct Diagnostics, Inc. is headquartered in Westport, Connecticut. The firm was formerly known as Solos Endoscopy, Inc., before adopting its current name in December 2020.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free